TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy

Int J Mol Sci. 2018 Mar 2;19(3):718. doi: 10.3390/ijms19030718.

Abstract

Galectin-1 (Gal-1) has been described to promote tumour growth by inducing angiogenesis and to contribute to the tumour immune escape. We had previously identified up-regulation of Gal-1 in preclinical models of aggressive neuroblastoma (NB), the most common extracranial tumour of childhood. While Gal-1 did not confer a survival advantage in the absence of exogenous stressors, Gal-1 contributed to enhanced cell migratory and invasive properties. Here, we review these findings and extend them by analyzing Gal-1 mediated effects on immune cell regulation and radiation resistance. In line with previous results, cell autonomous effects as well as paracrine functions contribute to Gal-1 mediated pro-tumourigenic functions. Interfering with Gal-1 functions in vivo will add to a better understanding of the role of the Gal-1 axis in the complex tumour-host interaction during immune-, chemo- and radiotherapy of neuroblastoma.

Keywords: Galectin-1; neuroblastoma; radiation response.

Publication types

  • Review

MeSH terms

  • Animals
  • Disease Models, Animal
  • Galectin 1 / genetics
  • Galectin 1 / metabolism*
  • Gene Dosage
  • Gene Expression Regulation, Neoplastic / radiation effects
  • Humans
  • Immunity* / genetics
  • Neovascularization, Pathologic / genetics
  • Neovascularization, Pathologic / immunology
  • Neovascularization, Pathologic / metabolism
  • Neuroblastoma / etiology*
  • Neuroblastoma / metabolism*
  • Neuroblastoma / radiotherapy
  • Phenotype
  • Radiation Tolerance* / genetics
  • Receptor, trkB / genetics
  • Receptor, trkB / metabolism*
  • Signal Transduction / radiation effects

Substances

  • Galectin 1
  • Receptor, trkB